Get 20% Off Journals at LWW.com

Glucocorticoid-mediated regulation of utrophin levels in human muscle fibers.

Neuromuscul Disord 2002 Oct;12 Suppl 1:S95-104

MyoContract Pharmaceutical Research Ltd., Klingelbergstrasse 70, CH-4056 Basel, Switzerland.

Previous studies on transgenic mice indicate that upregulation of utrophin protein may offer a potential treatment strategy for Duchenne muscular dystrophy. We have analyzed the effect of the glucocorticoid 6alpha-methylprednisolone-21 sodium succinate on utrophin protein levels, using a cell-based assay with differentiated human myotubes, derived from biopsies of healthy individuals or Duchenne muscular dystrophy patients. We found that within 5-7 days 6alpha-methylprednisolone-21 sodium succinate increases utrophin protein up to approximately 40% in both normal and dystrophin-deficient myotubes compared to untreated control cultures. When analyzed in promoter-reporter assays 6alpha-methylprednisolone-21 sodium succinate activated a utrophin promoter A-fragment but did not activate a utrophin promoter B-fragment. Surprisingly, endogenous levels of utrophin mRNA in 6alpha-methylprednisolone-21 sodium succinate-treated muscle cells were unaltered indicating that the utrophin-inducing effect of glucocorticoids may be a result of post-transcriptional mechanisms. We have also analyzed 66 glucocorticoids for their effect on utrophin protein levels and found that glucocorticoids in general are able to induce utrophin protein in human myotubes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-8966(02)00089-5DOI Listing
October 2002
Get 20% Off Journals at LWW.com

Similar Publications

Genome editing for Duchenne muscular dystrophy: a glimpse of the future?

Gene Ther 2021 Feb 2. Epub 2021 Feb 2.

Friedrich Baur Institute, Department of Neurology, LMU Munich, Munich, Germany.

Mutations in Dystrophin, one of the largest proteins in the mammalian body, are causative for a severe form of muscle disease, Duchenne Muscular Dystrophy (DMD), affecting not only skeletal muscle, but also the heart. In particular, exons 45-52 constitute a hotspot for DMD mutations. A variety of molecular therapies have been developed, comprising vectors encoding micro- and minidystrophins as well as utrophin, a protein with partially overlapping functions. Read More

View Article and Full-Text PDF
February 2021

Loss of sarcospan exacerbates pathology in mdx mice, but does not affect utrophin amelioration of disease.

Hum Mol Genet 2021 Jan 11. Epub 2021 Jan 11.

Department of Integrative Biology and Physiology, University of California, Los Angeles, CA 90095, USA.

The dystrophin-glycoprotein complex (DGC) is a membrane adhesion complex that provides structural stability at the sarcolemma by linking the myocyte's internal cytoskeleton and external extracellular matrix. In Duchenne muscular dystrophy (DMD), the absence of dystrophin leads to the loss of the DGC at the sarcolemma, resulting in sarcolemmal instability and progressive muscle damage. Utrophin, an autosomal homologue of dystrophin, is upregulated in dystrophic muscle and partially compensates for loss of dystrophin in muscle from patients with DMD. Read More

View Article and Full-Text PDF
January 2021

Aberrant RhoA activation in macrophages increases senescence-associated secretory phenotypes and ectopic calcification in muscular dystrophic mice.

Aging (Albany NY) 2020 12 23;12(24):24853-24871. Epub 2020 Dec 23.

Steadman Philippon Research Institute, Center for Regenerative Sports Medicine, Vail, CO 81657, USA.

Duchenne Muscular Dystrophy (DMD) patients often suffer from both muscle wasting and osteoporosis. Our previous studies have revealed reduced regeneration potential in skeletal muscle and bone, concomitant with ectopic calcification of soft tissues in double knockout (, ; utrophin-/-) mice, a severe murine model for DMD. We found significant involvement of RhoA/ROCK (Rho-Associated Protein Kinase) signaling in mediating ectopic calcification of muscles in mice. Read More

View Article and Full-Text PDF
December 2020

Decreasing HepG2 Cytotoxicity by Lowering the Lipophilicity of Benzo[d]oxazolephosphinate Ester Utrophin Modulators.

ACS Med Chem Lett 2020 Dec 4;11(12):2421-2427. Epub 2020 Nov 4.

Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford OX1 3TA, U.K.

Utrophin modulation is a disease-modifying therapeutic strategy for Duchenne muscular dystrophy that would be applicable to all patient populations. To improve the suboptimal profile of ezutromid, the first-in-class clinical candidate, a second generation of utrophin modulators bearing a phosphinate ester moiety was developed. This modification significantly improved the physicochemical and ADME properties, but one of the main lead molecules was found to have dose-limiting hepatotoxicity. Read More

View Article and Full-Text PDF
December 2020

PMO-based let-7c site blocking oligonucleotide (SBO) mediated utrophin upregulation in mdx mice, a therapeutic approach for Duchenne muscular dystrophy (DMD).

Sci Rep 2020 12 9;10(1):21492. Epub 2020 Dec 9.

Department of Physiology and Pennsylvania Muscle Institute, Perelman School of Medicine, University of Pennsylvania, 755 Clinical Research Building, Philadelphia, PA, 19104, USA.

Upregulation of utrophin, a dystrophin related protein, is considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD). Utrophin expression is repressed at the post-transcriptional level by a set of miRNAs, among which let-7c is evolutionarily highly conserved. We designed PMO-based SBOs complementary to the let-7c binding site in UTRN 3'UTR, with the goal of inhibiting let-7c interaction with UTRN mRNA and thus upregulating utrophin. Read More

View Article and Full-Text PDF
December 2020